The DOI matches its Crossref record; 21 of the 22 references it cites were found in a registry or an index.
Effects of Intravenous Ketamine on Explicit and Implicit Measures of Suicidality in Treatment-Resistant Depression
Open accessAbstract
Background Intravenous ketamine has shown rapid antidepressant effects in early trials, making it a potentially attractive candidate for depressed patients at imminent risk of suicide. The Implicit Association Test (IAT), a performance-based measure of association between concepts, may have utility in suicide assessment.Methods Twenty-six patients with treatment-resistant depression were assessed using the suicidality item of the Montgomery-Asberg Depression Rating Scale (MADRS-SI) 2 hours before and 24 hours following a single subanesthetic dose of intravenous ketamine. Ten patients also completed IATs assessing implicit suicidal associations at comparable time points. In a second study, nine patients received thrice-weekly ketamine infusions over a 12-day period.Results Twenty-four hours after a single infusion, MADRS-SI scores were reduced on average by 2.08 points on a 0 to 6 scale (p < .001; d = 1.37), and 81% of patients received a rating of 0 or 1 postinfusion. Implicit suicidal associations were also reduced following ketamine (p = .003; d = 1.36), with reductions correlated across implicit and explicit measures. MADRS-SI reductions were sustained for 12 days by repeated-dose ketamine (p < .001; d = 2.42).Conclusions These preliminary findings support the premise that ketamine has rapid beneficial effects on suicidal cognition and warrants further study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ketamine's half-life in the body is ;2 h (Autry et al., 2011), yet a single low-dose treatment elicits sustained (.1 week) antidepressant effects in patients (Berman et al., 2000;Zarate et al., 2006;Price et al., 2009), strongly suggesting it induces neuroplasticity (Duman, 2018).”
From Psychedelics and Neural Plasticity: Therapeutic Implications (2022) · cites this paper as Price et al., 2009
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Ketamine rapidly induces flexibility in implicit representations of self on the Implicit Association Test 134,135 , and these shifts correlated with self-reported symptom improvements 110 , suggesting that ketamine can immediately impact the structure of implicit mental representations relevant to one's concept of self, a core form of cognitive bias in depression.”
From Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model (2020) · cites this paper as [135]
In the citing paper
“Critically, several versions of the IAT have also been incorporated into clinical ketamine trials, which found that the “escape” version of the IAT (instead of “death,” the participant links the self with “escape” or “stay”) was associated with reductions in SI (57, 58).”
From New methods for assessing rapid changes in suicide risk (2021) · cites this paper as [57]
In the citing paper
“Administration of glutamate receptor antagonists, such as the NMDA antagonist, ketamine, have potent antidepressant effects especially in treatment resistant depressed patients”
From Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications (2013) · cites this paper as Price et al., 2009
In the citing paper
“Recent studies report that ketamine also reduces suicide ideation, a major advance over typical antidepressants with low efficacy and delayed onset of action151,152.”
From Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants (2016) · cites this paper as [152]
In the citing paper
“Ketamine has been also shown to induce a rapid amelioration of suicidal ideation in major depressed patients 23, 24”
From Mechanisms of ketamine action as an antidepressant (2018) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Power Analysis for the Behavioral Sciences
Muller, K. E., & Cohen, J. (1989) · Technometrics · doi:10.2307/1270020 · Cited by 99,603
Statistical power analysis for the behavioral sciences
Cohen, J. (1990) · Computers Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,417
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Measuring individual differences in implicit cognition: the implicit association test
Greenwald, A. G., McGhee, D. E., & Schwartz, J. L. K. (1998) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.74.6.1464 · Cited by 9,210
Understanding and using the Implicit Association Test: I. An improved scoring algorithm.
Greenwald, A. G., Nosek, B. A., & Banaji, M. R. (2003) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.85.2.197 · Cited by 5,815
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
Self-citationA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationUnderstanding and using the Implicit Association Test: III. Meta-analysis of predictive validity.
Greenwald, A. G., Poehlman, T. A., Uhlmann, E. L., & Banaji, M. R. (2009) · Journal of Personality and Social Psychology · doi:10.1037/a0015575 · Cited by 3,257
The Inventory of Depressive Symptomatology (IDS): Psychometric properties
Rush, A. J., Gullion, C. M., Basco, M. R., Jarrett, R. B., & Trivedi, M. H. (1996) · Psychological Medicine · doi:10.1017/s0033291700035558 · Cited by 2,177
Understanding and Using the Implicit Association Test: II. Method Variables and Construct Validity
Nosek, B. A., Greenwald, A. G., & Banaji, M. R. (2004) · Personality and Social Psychology Bulletin · doi:10.1177/0146167204271418 · Cited by 1,216
Cited by
Sorted by citations
Items 101–200 of 601
New targets for rapid antidepressant action
Machado‐Vieira, R., Henter, I. D., & Zarate, C. A. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.12.001 · Cited by 161
Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder
Niciu, M. J., Ionescu, D. F., Richards, E. M., & Zarate, C. A. (2013) · Journal of Neural Transmission · doi:10.1007/s00702-013-1130-x · Cited by 163
Neuroinflammation in suicide: Toward a comprehensive model
Courtet, P., Giner, L., Seneque, M., Guillaume, S., Olie, E., & Ducasse, D. (2016) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2015.1054879 · Cited by 146
Li, Y.-F. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107494 · Cited by 158
Antidepressant actions of ketamine: from molecular mechanisms to clinical practice
Monteggia, L. M., & Zarate, C. (2015) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2014.12.004 · Cited by 149
Ghasemi, M., Kazemi, M., Yoosefi, A., Ghasemi, A., Paragomi, P., Amini, H., & Afzali, M. H. (2013) · Psychiatry Research · doi:10.1016/j.psychres.2013.12.008 · Cited by 155
Hu, Y.-D., Xiang, Y.-T., Fang, J.-X., Zu, S., Sha, S., Shi, H., Ungvari, G. S., Correll, C. U., Chiu, H. F. K., Xue, Y., et al. (2016) · Psychological Medicine · doi:10.1017/s0033291715002159 · Cited by 146
Anhedonia as a clinical correlate of suicidal thoughts in clinical ketamine trials
Ballard, E. D., Wills, K. E., Lally, N., Richards, E. M., Luckenbaugh, D. A., Walls, T. L., Ameli, R., Niciu, M. J., Brutsché, N. E., Park, L., et al. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.04.057 · Cited by 155
Neuronal correlates of depression
Chaudhury, D., Liu, H., & Han, M. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2044-6 · Cited by 150
Dakwar, E., Levin, F., Foltin, R. W., Nunes, E. V., & Hart, C. L. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.08.009 · Cited by 143
Kohtala, S. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00232-4 · Cited by 155
Ma, Z., Zang, T., Birnbaum, S. G., Wang, Z., Johnson, J. E. B., Zhang, C., & Parada, L. F. (2017) · Nature Communications · doi:10.1038/s41467-017-01709-8 · Cited by 141
Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status
Henter, I. D., Park, L. T., & Zarate, C. A. (2021) · CNS Drugs · doi:10.1007/s40263-021-00816-x · Cited by 142
Ross, S., Agin-Liebes, G., Lo, S., Zeifman, R. J., Ghazal, L., Benville, J., Franco Corso, S., Bjerre Real, C., Guss, J., Bossis, A., et al. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00020 · Cited by 139
Caddy, C., Giaroli, G., White, T. P., Shergill, S. S., & Tracy, D. K. (2013) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125313507739 · Cited by 145
Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants
Gould, T. D., Zarate, C. A., & Thompson, S. M. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-052811 · Cited by 133
An update on ketamine and its two enantiomers as rapid-acting antidepressants
Zhang, K., & Hashimoto, K. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1554434 · Cited by 132
Automaticity in anxiety disorders and major depressive disorder
Teachman, B. A., Joormann, J., Steinman, S. A., & Gotlib, I. H. (2012) · Clinical Psychology Review · doi:10.1016/j.cpr.2012.06.004 · Cited by 130
Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression
Lener, M. S., Kadriu, B., & Zarate, C. A. (2017) · Drugs · doi:10.1007/s40265-017-0702-8 · Cited by 131
Ketamine as a new treatment for depression: A review of its efficacy and adverse effects
Katalinic, N., Lai, R., Somogyi, A. A., Mitchell, P. B., Glue, P., & Loo, C. K. A. (2013) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867413486842 · Cited by 132
Kranaster, L., Kammerer-Ciernioch, J., Hoyer, C., & Sartorius, A. (2011) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-011-0205-7 · Cited by 129
Molecular aspects of depression: A review from neurobiology to treatment
Boas, G. R. V., de Lacerda, R. B., Paes, M. M., Gubert, P., Almeida, W. L. D. C., Rescia, V. C., Galdino, P. M., de Carvalho, A. A. V., & Oesterreich, S. A. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.02.024 · Cited by 140
Chandley, M., Szebeni, A., Szebeni, K., Crawford, J. D., Stockmeier, C. A., Turecki, G., Kostrzewa, R. M., & Ordway, G. A. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000662 · Cited by 139
AMPA Receptor Activation–Independent Antidepressant Actions of Ketamine Metabolite (S)-Norketamine
Yang, C., Kobayashi, S., Nakao, K., Dong, C., Han, M., Qu, Y., Ren, Q., Zhang, J.-C., Ma, M., Toki, H., et al. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.05.007 · Cited by 128
Bogenschutz, M. P., & Pommy, J. M. (2012) · Drug Testing and Analysis · doi:10.1002/dta.1376 · Cited by 130
The role of NMDA receptors in the pathophysiology and treatment of mood disorders
Ghasemi, M., Phillips, C., Trillo, L., Miguel, Z. D., Das, D., & Salehi, A. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.08.017 · Cited by 132
Lee, E. E., Della Selva, M. P., Liu, A., & Himelhoch, S. (2015) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2015.01.003 · Cited by 124
Therapeutic infusions of ketamine: do the psychoactive effects matter?
Dakwar, E., Anerella, C., Hart, C. L., Levin, F. R., Mathew, S. J., & Nunes, E. V. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2013.12.019 · Cited by 123
Bobo, W. V., Voort, J. L. V., Croarkin, P. E., Leung, J. G., Tye, S. J., & Frye, M. A. (2016) · Depression and Anxiety · doi:10.1002/da.22505 · Cited by 123
Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder
Papakostas, G. I., & Ionescu, D. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.92 · Cited by 126
Ketamine as a Potential Treatment for Suicidal Ideation: A Systematic Review of the Literature
Reinstatler, L., & Youssef, N. A. (2015) · Drugs in R&D · doi:10.1007/s40268-015-0081-0 · Cited by 120
Design of fast-onset antidepressant by dissociating SERT from nNOS in the DRN
Sun, N., Qin, Y., Chu, X., Xia, T., Du, Z., Zheng, L., Li, A., Meng, F. J., Zhang, Y., Zhang, J., et al. (2022) · Science · doi:10.1126/science.abo3566 · Cited by 124
Ketamine as a promising prototype for a new generation of rapid‐acting antidepressants
Abdallah, C. G., Averill, L. A., & Krystal, J. H. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12718 · Cited by 121
Orozco-Solis, R., Montellier, E., Aguilar-Arnal, L., Sato, S., Vawter, M. P., Bunney, B. G., Bunney, W. E., & Sassone-Corsi, P. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.02.1176 · Cited by 119
Benedetti, F., Riccaboni, R., Locatelli, C., Poletti, S., Dallaspezia, S., & Colombo, C. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08455 · Cited by 116
The role of dopamine in inflammation-associated depression: mechanisms and therapeutic implications
Felger, J. C. (2016) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2016_13 · Cited by 115
Ketamine as a rapid-acting agent for suicidal ideation: A meta-analysis
Bartoli, F., Riboldi, I., Crocamo, C., Brita, C. D., Clerici, M., & Carrà, G. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.03.010 · Cited by 114
How does ketamine elicit a rapid antidepressant response?
Kavalali, E. T., & Monteggia, L. M. (2014) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.11.005 · Cited by 113
Administration of ketamine for unipolar and bipolar depression
Kraus, C., Rabl, U., Vanicek, T., Carlberg, L., Popovic, A., Spies, M., Bartova, L., Gryglewski, G., Papageorgiou, K., Lanzenberger, R. R., et al. (2017) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2016.1254802 · Cited by 114
Zunszain, P. A., Horowitz, M. A., Cattaneo, A., Lupi, M., & Pariante, C. M. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.87 · Cited by 110
Zeifman, R. J., Wagner, A. C., Watts, R., Kettner, H., Mertens, L. J., & Carhart-Harris, R. L. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00782 · Cited by 106
Classics in Chemical Neuroscience: Fluoxetine (Prozac)
Wenthur, C. J., Bennett, M. R., & Lindsley, C. W. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn400186j · Cited by 108
Classics in Chemical Neuroscience: Ketamine
Tyler, M. W., Yourish, H. B., Ionescu, D. F., & Haggarty, S. J. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00074 · Cited by 108
Lateral Habenular Burst Firing as a Target of the Rapid Antidepressant Effects of Ketamine
Cui, Y., Hu, S., & Hu, H. (2019) · Trends in Neurosciences · doi:10.1016/j.tins.2018.12.002 · Cited by 111
Cultural Differences and Information Technology Acceptance
Zakour, A. B. (2004) · Cited by 101
Faster, better, stronger: Towards new antidepressant therapeutic strategies
O’Leary, O. F., Dinan, T. G., & Cryan, J. F. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.046 · Cited by 104
Cognition and self-injurious thoughts and behaviors: a systematic review of longitudinal studies
Cha, C. B., Wilson, K. M., Tezanos, K. M., DiVasto, K. A., & Tolchin, G. K. (2019) · Clinical Psychology Review · doi:10.1016/j.cpr.2018.07.002 · Cited by 94
Involvement of Sigma-1 Receptors in the Antidepressant-like Effects of Dextromethorphan
Nguyen, L., Robson, M. J., Healy, J. R., Scandinaro, A. L., & Matsumoto, R. R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089985 · Cited by 99
From synapse to nucleus: Novel targets for treating depression
Covington, H. E., Vialou, V., & Nestler, E. J. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.12.004 · Cited by 98
Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder
Jaso, B. A., Niciu, M. J., Iadarola, N. D., Lally, N., Richards, E. M., Park, M., Ballard, E. D., Nugent, A. C., Machado‐Vieira, R., & Zarate, C. A. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666160321123221 · Cited by 101
Wilkinson, S. T., Holtzheimer, P. E., Gao, S., Kirwin, D. S., & Price, R. B. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.09.004 · Cited by 95
Self-citationRobson, M. J., Elliott, M., Seminerio, M. J., & Matsumoto, R. R. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.08.002 · Cited by 95
RYBAKOWSKI, J. K., Permoda‐Osip, A., Skibińska, M., Adamski, R., & Bartkowska‐Śniatkowska, A. (2012) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2271 · Cited by 92
Neuroplasticity and the next wave of antidepressant strategies
Hayley, S., & Litteljohn, D. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00218 · Cited by 92
Novel glutamatergic agents for major depressive disorder and bipolar disorder
Machado-Vieira, R., Ibrahim, L., Henter, I. D., & Zarate, C. A. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.09.010 · Cited by 92
Ago, Y., Tanabe, W., Higuchi, M., Tsukada, S., Tanaka, T., Yamaguchi, T., Igarashi, H., Yokoyama, R., Seiriki, K., Kasai, A., et al. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz041 · Cited by 92
Acute d-serine treatment produces antidepressant-like effects in rodents
Malkesman, O., Austin, D. R., Tragon, T. R., Wang, G., Rompala, G. R., Hamidi, A., Cui, Z., Young, W. S., Nakazawa, K., Zarate, C. A., et al. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001386 · Cited by 93
Freudenberg, F., Celikel, T., & Reif, A. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.03.005 · Cited by 97
Glutamatergic Modulators in Depression
Henter, I. D., SOUSA, R. T. D., & Zarate, C. A. (2018) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000183 · Cited by 99
Role of Inflammation in Depression and Treatment Implications
Felger, J. C. (2018) · Handbook of experimental pharmacology · doi:10.1007/164_2018_166 · Cited by 94
The promise of ketamine for treatment‐resistant depression: current evidence and future directions
DeWilde, K. E., Levitch, C. F., Murrough, J. W., Mathew, S. J., & Iosifescu, D. V. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12646 · Cited by 95
Self-citationAmidfar, M., Woelfer, M., Réus, G. Z., Quevedo, J., Walter, M., & Kim, Y. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109668 · Cited by 95
The impact of Ayahuasca on suicidality: results from a randomized controlled trial
Zeifman, R. J., Palhano-Fontes, F., Hallak, J., Arcoverde, E., Maia-Oliveira, J. P., & Araujo, D. B. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01325 · Cited by 87
Acute Antidepressant Effects of Intramuscular Versus Intravenous Ketamine
Chilukuri, H., Reddy, N. P., Pathapati, R. M., Manu, A. N., Jollu, S., & Shaik, A. B. (2014) · Indian Journal of Psychological Medicine · doi:10.4103/0253-7176.127258 · Cited by 89
Psychedelics and Neural Plasticity: Therapeutic Implications
Grieco, S. F., Castrén, E., Knudsen, G. M., Kwan, A. C., Olson, D. E., Zuo, Y., Holmes, T. C., & Xu, X. (2022) · The Journal of Neuroscience · doi:10.1523/jneurosci.1121-22.2022 · Cited by 82
“1 week) anti-depressant effects in patients (Berman et al., 2000; Zarate et al., 2006; Price et al., 2009), strongly suggesting it induces neuroplasticity (Duman, 2018).”
Domany, Y., Shelton, R. C., & McCullumsmith, C. B. (2020) · Depression and Anxiety · doi:10.1002/da.22975 · Cited by 84
Price, R. B., Spotts, C., Panny, B., Griffo, A., Degutis, M., Cruz, N., Bell, E., Do-Nguyen, K., Wallace, M. L., Mathew, S. J., et al. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20220216 · Cited by 85
Self-citationBettio, L. E. B., Cunha, M. P., Budni, J., Pazini, F. L., Oliveira‐Giacomelli, Á., Colla, A. R. D. S., & Rodrigues, A. L. S. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.06.021 · Cited by 84
Guo, M., Lu, Y., Garza, J. C., Li, Y., Chua, S. C., Zhang, W., Lu, B., & Lu, X.-Y. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.9 · Cited by 84
Glutamate-Modulating Drugs as a Potential Therapeutic Strategy in Obsessive-Compulsive Disorder
Marinova, Z., Chuang, D.-M., & Fineberg, N. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170320104237 · Cited by 83
The PSD-95/nNOS complex: New drugs for depression?
Doucet, M. V., Harkin, A., & Dev, K. K. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.11.005 · Cited by 84
Larkin, G. L., Beautrais, A. L., Turelli, R., Sanacora, G., Powsner, S. M., Lippmann, M. J., & Krystal, J. H. (2011) · European Psychiatry · doi:10.1016/s0924-9338(11)73311-9 · Cited by 80
Rapid-acting antidepressant strategies: mechanisms of action
Bunney, B. G., & Bunney, W. E. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000927 · Cited by 79
Amat, J., Dolzani, S. D., Tilden, S. G., Christianson, J. P., Kubala, K. H., Bartholomay, K. L., Sperr, K., Ciancio, N., Watkins, L. R., & Maier, S. F. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.3114-15.2016 · Cited by 85
Zurek, A. A., Bridgwater, E. M., & Orser, B. A. (2012) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e31824720da · Cited by 79
Pharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines
Taylor, R. W., Marwood, L., Oprea, E., DeAngel, V., Mather, S., Valentini, B., Zahn, R., Young, A. H., & Cleare, A. J. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa033 · Cited by 76
Xue, W., Zhou, X., Yi, N., Jiang, L., Tao, W., Wu, R., Wang, D., Jiang, J., Ge, X., Wang, Y., et al. (2013) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2013/184367 · Cited by 77
Visentin, A. P. V., Colombo, R., Scotton, E., Fracasso, D. S., Rosa, A. R., Branco, C. S., & Salvador, M. M. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/2972968 · Cited by 77
Noradrenergic Dysfunction in Depression and Suicide
Chandley, M., & Ordway, G. A. (2012) · Frontiers in neuroscience · doi:10.1201/b12215-4 · Cited by 79
A New Perspective on the Anti-Suicide Effects With Ketamine Treatment: A Procognitive Effect
Lee, Y., Syeda, K., Maruschak, N. A., Cha, D. S., Mansur, R. B., Wium-Andersen, I. K., Woldeyohannes, H. O., Rosenblat, J. D., & McIntyre, R. S. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000441 · Cited by 74
Yamamoto, S., Ohba, H., Nishiyama, S., Harada, N., Kakiuchi, T., Tsukada, H., & Domino, E. F. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.176 · Cited by 73
Rincón‐Cortés, M., & Grace, A. A. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.112367 · Cited by 72
Li, Y., Zhu, Z. R., Ou, B. C., Wang, Y. Q., Tan, Z. B., Deng, C. M., Gao, Y., Tang, M., So, J. H., Mu, Y., et al. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.11.016 · Cited by 74
Picard, N., Takesian, A. E., Fagiolini, M., & Hensch, T. K. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0341-9 · Cited by 71
Nikkheslat, N. (2021) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2021.100383 · Cited by 72
Monteggia, L. M., Malenka, R. C., & Deisseroth, K. A. (2014) · Nature · doi:10.1038/515200a · Cited by 69
Ketamine Influences CLOCK:BMAL1 Function Leading to Altered Circadian Gene Expression
Bellet, M. M., Vawter, M. P., Bunney, B. G., Bunney, W. E., & Sassone-Corsi, P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023982 · Cited by 70
Is There Anything Really Novel on the Antidepressant Horizon?
Murrough, J. W., & Charney, D. S. (2012) · Current Psychiatry Reports · doi:10.1007/s11920-012-0321-8 · Cited by 70
Self-citationNovel rapid-acting glutamatergic modulators: Targeting the synaptic plasticity in depression
Wang, Y., Wang, X., Feng, S., Chen, N., Wang, Z., & Zhang, Y. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105761 · Cited by 68
Altered Chemokine Levels in the Cerebrospinal Fluid and Plasma of Suicide Attempters
Janelidze, S., Ventorp, F., Erhardt, S., Hansson, O., Minthon, L., Flax, J., Samuelsson, M., Traskman-Bendz, L., & Brundin, L. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2012.09.010 · Cited by 69
Burger, J., Capobianco, M., Lovern, R., Boche, B., Ross, E. M., Darracq, M. A., & McLay, R. N. (2016) · Military Medicine · doi:10.7205/milmed-d-15-00431 · Cited by 71
Lv, Q., Yang, L., Li, G., Wang, Z., Shen, Z., Yu, W., Jiang, Q., Hou, B., Pu, J., Hu, H., et al. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.02.028 · Cited by 70
Anand, A., Gunn, A. D., Barkay, G., Karne, H. S., Nürnberger, J. I., Mathew, S. J., & Ghosh, S. (2012) · Bipolar Disorders · doi:10.1111/j.1399-5618.2011.00971.x · Cited by 69
Self-citationHartberg, J., Garrett-Walcott, S., & Gioannis, A. D. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4786-3 · Cited by 66
Antidepressant mechanism of ketamine: perspective from preclinical studies
Scheuing, L., Chiu, C., Liao, H., & Chuang, D. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00249 · Cited by 66
Chen, G., Chen, L., Zhang, Y., Li, X., Lane, R., Lim, P., Daly, E. J., Furey, M. L., Fedgchin, M., Popova, V., et al. (2022) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab084 · Cited by 66
A unified model of ketamine’s dissociative and psychedelic properties
Marguilho, M., Figueiredo, I., & Castro-Rodrigues, P. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221140011 · Cited by 71
O'Connor, E. J., Gaynes, B. N., Bu, B., Williams, C., & Ep, W. (2013) · Cited by 64
Koike, H., Iijima, M., & Chaki, S. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.03.017 · Cited by 68
An update on NMDA antagonists in depression
Pochwat, B., Nowak, G., & Szewczyk, B. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1643237 · Cited by 67
Metadata
- Authors
- Price, R. B., Nock, M. K., Charney, D. S., & Mathew, S. J.
- Affiliations
- Rutgers, The State University of New Jersey (US)
- Harvard University (US)
- Icahn School of Medicine at Mount Sinai (US)
- Corresponding author
- Price, Rebecca B.
- Venue
- Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2009-09
- Volume
- 66
- Issue
- 5
- Pages
- 522-526
- ISSN
- 0006-3223 (ISSN-L)
- PMC
- PMC2935847
- OpenAlex
- W2118815581
- Cited by
- 600
- References
- 22
- Citations by year
- 2026: 15 · 2025: 16 · 2024: 18 · 2023: 25 · 2022: 43 · 2021: 49 · 2020: 43 · 2019: 39 · 2018: 31 · 2017: 34 · 2016: 46 · 2015: 62 · 2014: 45 · 2013: 42 · 2012: 43
- FWCI
- 21.80
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Biological Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- National Institutes of Health (F31 MH081468, K23-MH-069656, MO1-RR-00071)
- National Alliance for Research on Schizophrenia and Depression
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- intravenous ketamine, treatment-resistant depression, suicidality, suicide risk, Implicit Association Test, rapid antidepressant effects, suicide assessment
- MeSH terms
- Suicide Prevention, Depression, Drug Resistance, Female, Humans, Infusions, Intravenous, Ketamine, Male, Middle Aged, Psychiatric Status Rating Scales, Suicide, Cohort Studies, Excitatory Amino Acid Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
